||Identification of novel antiviral of fungus-derived brefeldin A against dengue viruses
Raekiansyah, Muhareva ,
Mori, Mihoko ,
Nonaka, Kenichi ,
Agoh, Masanobu ,
Shiomi, Kazuro ,
Matsumoto, AtsukoMorita, Kouichi
Tropical Medicine and Health
45p.32 , 2017-10-26 , BioMed Central Ltd.
Microbial natural products possess a wide range of biological and biochemical potential. Among them, fungal secondary metabolites are one of the most important sources for discovering new drugs or lead compounds. In the present study, we explored substances produced by the strain Penicillium sp. FKI-7127 for its antiviral activity. We identified brefeldin A as a novel antiviral agent against dengue viruses. The inhibitory effect of brefeldin A was confirmed by virus titer and immunofluorescence assay. Brefeldin A inhibited dengue viruses regardless of serotypes and other related viruses including Zika virus and Japanese encephalitis virus. Time-of-addition study showed that brefeldin A exerts its antiviral effect at an early stage of the dengue virus (DENV) life cycle. These studies demonstrate that (i) brefeldin A could be used as a lead compound for drug development of anti-DENV and other related viruses and (ii) fungal metabolites are a potential and valuable source for dengue virus drug discovery.